Chapter 10
Enzyme Inhibition in Various In Vitro Systems
Book Editor(s):Chuang Lu,
Albert P. Li,
Chuang Lu
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorAlbert P. Li
In Vitro ADMET Laboratories, Columbia, Maryland, USA
Search for more papers by this authorFirst published: 14 December 2009
Summary
This chapter contains sections titled:
-
Introduction
-
Preparation of Liver Samples
-
In Vitro Experimental Design
-
Application of in Vitro Hepatic Systems in Studying Inhibition of Drug Metabolizing Enzymes
-
Conclusion
-
References
REFERENCES
- Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of non-specific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab Dispos 2002; 30: 1497–1503.
- Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 2005; 33: 419–425.
- Berry MN, Friend DS. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 1969; 43(3): 506–520.
- Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31(7): 815–832.
- Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007; 35: 293–301.
- Chen TL, Wu CH, Chen TG, Tai YT, Chang HC, Lin CJ. Effects of propofol on functional activities of hepatic and extrahepatic conjugation enzyme systems. Br J Anaesth 2000; 84(6): 771–776.
- de Kanter R, Monshouwer M, Meijer DK, Groothuis GM. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr Drug Metab 2002a; 3(1): 39–59.
- de Kanter R, De Jager MH, Draaisma AL, Jurva JU, Olinga P, Meijer DK, Groothuis GM. Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices. Xenobiotica 2002b; 32(5): 349–362.
- Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000; 28: 560–566.
- Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 2006; 34(4): 724–726.
- Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007; 39(1): 159–234.
- Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab Dispos 2005; 33(2): 287–293.
- Holleran JL, Fourcade J, Egorin MJ, Eiseman JL, Parise RA, Musser SM, White KD, Covey JM, Forrest GL, Pan SS. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metab Dispos 2004; 32(5): 490–496.
- Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug—drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50(3): 387–412.
- Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug—drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004; 32(11): 1311–1316.
- Lam JL, Okochi H, Huang Y, Benet LZ. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter—enzyme interplay. Drug Metab Dispos 2006; 34(8): 1336–1344.
- LeCluyse EL, Audus KL, Hochman JH. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 1994; 266(6 Pt 1): C1764–C1774.
- LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L. Isolation and culture of primary human hepatocytes. Methods Mol Biol 2005; 290: 207–229.
- Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug—drug interaction potential. Chem Biol Interact 1999; 121(1): 17–35.
- Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 2007a; 35(7): 1023–1031.
- Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 2007b; 35(7): 1203–1208.
- Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1999; 35(5): 361–390.
- Liu X, Brouwer KL, Gan LS, Brouwer KR, Stieger B, Meier PJ, Audus KL, LeCluyse EL. Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm Res 1998; 15(10): 1533–1539.
- Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999a; 27(6): 637–644.
- Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, Brouwer KL. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 1999b; 289(3): 1592–1599.
- Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague—Dawley rat, minipig, and beagle dog. Chem Biol Interact 2001;16; 134(3): 271–281.
- Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 2006; 34(9): 1600–1605
- Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug—drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 2007; 35(1): 79–85
- Lu C, Hatsis P, Berg C, Lee FW, Balani SK. Prediction of pharmacokinetic drug—drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro—in vivo correlation with ketoconazole. Drug Metab Dispos 2008; 36(7): 1255–1260
- McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004; 32(11): 1247–1253.
- McGinnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug—drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005; 33(11): 1700–1707.
- Nagai M, Conney AH, Zhu BT. Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase. Drug Metab Dispos 2004; 32(5): 497–504.
- Neve EP, Ingelman-Sundberg M. Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). J Biol Chem 2001; 276(14): 11317–11322.
- Obach RS. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism and implications for in vitro—in vivo correlations. Drug Metab Dispos 1996; 24: 1047–1049.
- Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 1997; 25(12): 1359–1369.
- Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350–1359.
- Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 2004; 32(1): 89–97.
- Obach RS, Walsky RL. Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone: an in vitro study. J Clin Psychopharmacol 2005; 25(6): 605–608.
- Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 2008; 36(7): 1365–1374.
- Porter SJ, Somogyi AA, White JM. Kinetics and inhibition of the formation of 6betanaltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 2000; 50(5): 465–471.
- Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005; 33: 1304–1311.
- Ren S, Slatterly JT. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS PharmSci. (3) article 14 (http://www.pharmsci.org)
- Robin MA, Anandatheerthavarada HK, Fang JK, Cudic M, Otvos L, Avadhani NG. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J Biol Chem 2001; 276(27): 24680–24689.
- Segel, JH. Enzyme Kinetics. John Wiley & Sons, New York: 1975, p. 127.
- Silverman, RB. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. Boca Raton, FL: CRC Press.
- Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T. Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 2004; 32(10): 1103–1110.
- Tucker GT, Houston JB, Huang S-M. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Clin Pharmacol Ther 2001; 70: 103–114.
- Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL. Hepatobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 2006; 318(2): 881–889.
- Van LM, Swales J, Hammond C, Wilson C, Hargreaves JA, Rostami-Hodjegan A. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). Eur J Pharm Sci 2007; 31(1): 53–61.
- Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 2003; 55(2): 191–198.
- Ward ES, Pollack GM, Brouwer KL. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? Drug Metab Dispos 2000; 28(12): 1433–1439.
- Yamazaki S, Toth LN, Black ML, Duncan JN. Comparison of prediction methods for in vivo clearance of (S, S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab Dispos 2004; 32(4): 398–404.
- Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005; 33(6): 853–861.
- Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 2007; 35(5): 704–712.
- Zhao P. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 2008; 4(2): 151–164. Review.
